Contact SCGE




SCGE Consortium Home   |  About SCGE Toolkit   |  Contact Us   |  Citing the Toolkit   |  License  
ExperimentComparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to sgRNA ratio (CMV promoter) and self complementary sgRNA vector.
Experiment ConditionAAV9, Male
Assay Description: Editing efficiency calculated by counting fluorescent cells (TdTomato) compared to DAPI stained cells.
Tissue Measured:heart
Measurement Type:Editing Efficiency
Record ID15000001034

EditorSaCas9-Lagor
Delivery System
Delivery System Subtype
Guide
VectorAAV9-CMV-SaCas9; AAV9_pTR_self comp 2xU6-Ai9 guides;

Model SpeciesMouse
Model NameB6.Cg-Gt(ROSA)26Sor ^ tm9(CAG-tdTomato)Hze/J

Application Methodintravenous
Application Siteliver and heart
Dosage2e12vg of CMV Sacas9 vector and 2e12vg of the self complementary sgRNA vector
Injection Frequencyonce
Injection Rate
Injection Volume200 microliters
Days post injection4 weeks
Editor FormatAAV vector encoded
Antidote Id
Antidote Description

Measured Values
Samples Size: 2
 
Replicate Result (Editing Efficiency)
Measurement Units: % of cells
Mean 1.36 
1 1.43978110277482 
2 1.29021072526254 
  

Publication Title
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. NCBI
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. NCBI
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. NCBI
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. NCBI
Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. NCBI